CN108137684A - 抗ox40抗体及其应用 - Google Patents
抗ox40抗体及其应用 Download PDFInfo
- Publication number
- CN108137684A CN108137684A CN201580083716.5A CN201580083716A CN108137684A CN 108137684 A CN108137684 A CN 108137684A CN 201580083716 A CN201580083716 A CN 201580083716A CN 108137684 A CN108137684 A CN 108137684A
- Authority
- CN
- China
- Prior art keywords
- sequence
- variable region
- chain variable
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
重链 | 轻链 |
H7位:S突变成L | L30位:S突变成G |
H13位:K突变成M | L90位:L突变成Q |
H28位:S突变成N | |
H33位:S突变成G | |
H43位:R突变成G | |
H65位:S突变成N | |
H67位:I突变成M | |
H96位:N突变成D |
名称 | Kon(1/Ms) | Koff(1/s) | KD(M) |
O3mAb | 2.84E+05 | 3.91E-04 | 1.378E-09 |
O21mAb | 4.181E+4 | 6.077E-04 | 1.454E-08 |
VHnew-L80 | 3.329E+04 | 3.415E-04 | 1.026E-08 |
H96-L80 | 2.999E+04 | 2.368E-04 | 7.898E-09 |
Claims (24)
- 一种抗OX40抗体或其抗原结合部分,其特征在于:其包括选自如下一组的CDR区:1)其重链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:5-7所示,轻链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:14-16所示,或者其重链可变区和轻链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%;2)其重链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:23-25所示,轻链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:32-34所示,或者其重链可变区和轻链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%;3)其重链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:41-43所示,轻链可变区CDR1、CDR2、CDR3的序列分别如SEQ ID NO:50-52所示,或者其重链可变区和轻链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求1所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的重链可变区,其序列如SEQ ID NO:4、22和40所示,或者其重链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求2所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的重链可变区,其序列如SEQ ID NO:4、22和40所示,或者其重链可变区CDR区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)突变氨基酸的个数不超过3个。
- 根据权利要求3所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的重链可变区,其序列如SEQ ID NO:4、22、40、62、66、69、72和79所示。
- 根据权利要求1所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的轻链可变区,其序列如SEQ ID NO:13、31和49所示,或者其轻链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求5所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的轻链可变区,其序列如SEQ ID NO:13、31和49所示,或者其轻链可变区CDR区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)突变氨基酸的个数不超过3个。
- 根据权利要求6所述的抗OX40抗体或其抗原结合部分,其特征在于:包括选自于如下一组的轻链可变区,其序列如SEQ ID NO:13、31、49和74所示。
- 根据权利要求1所述的抗OX40抗体或其抗原结合部分,其特征在于:其为全抗体、双特异性抗体、scFv、Fab、Fab′、F(ab′)2或Fv。
- 根据权利要求8所述的抗OX40抗体或其抗原结合部分,其特征在于:当其为scFv时,其重链和轻链可变区之间可含有连接肽。
- 根据权利要求1所述的抗OX40抗体或其抗原结合部分,其特征在于:其重链恒定区选自IgG、IgM、IgE、IgD和IgA。
- 根据权利要求1所述的抗OX40抗体或其抗原结合部分,其特征在于:其轻链恒定区为κ或λ。
- 一种核酸分子,其特征在于:其包含能够编码抗体重链可变区的核酸序列,所述重链可变区包含选自如下一组的氨基酸序列:(1)SEQ ID NO:5-7;(2)SEQ ID NO:23-25;(3)SEQ ID NO:41-43;(4)与前述(1)~(3)序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求13所述的核酸分子,其特征在于:所述重链可变区包含选自如下一组的氨基酸序列:SEQ ID NO:4、22和40,或与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求14所述的核酸分子,其特征在于:包括选自于如下一组的重链可变区,其序列如SEQ ID NO:4、22和40所示,或者其重链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)突 变氨基酸的个数不超过3个。
- 根据权利要求15所述的核酸分子,其特征在于:包括选自于如下一组的重链可变区,其序列如SEQ ID NO:4、22、40、62、66、69、72和79所示。
- 一种核酸分子,其特征在于:其包含能够编码抗体轻链可变区的核酸序列,所述轻链可变区包含选自如下一组的氨基酸序列:(1)SEQ ID NO:14-16;(2)SEQ ID NO:32-34;(3)SEQ ID NO:50-52;(4)与前述(1)~(3)序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求17所述的核酸分子,其特征在于:所述重链可变区包含选自如下一组的氨基酸序列:SEQ ID NO:13、31和49,或与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)同一性大于70%、80%、85%、90%或97%。
- 根据权利要求18所述的核酸分子,其特征在于:包括选自于如下一组的轻链可变区,其序列如SEQ ID NO:13、31和49所示,或者其轻链可变区与前述序列相比满足以下二者中至少一个的序列:a)结合相同抗原表位;b)突变氨基酸的个数不超过3个。
- 根据权利要求19所述的核酸分子,其特征在于:包括选自于如下一组的轻链可变区,其序列如SEQ ID NO:13、31、49和74所示。
- 一种载体,其特征在于:其含有权利要求13-20任一项的核酸分子。
- 一种宿主细胞,其特征在于:其含有权利要求13-20任一项的核酸分子或权利要求21的载体。
- 一种偶联物,其特征在于:其含有权利要求1-12任一项的抗OX40抗体或其抗原结合部分,以及其它生物活性物质,所述抗OX40抗体或其抗原结合部分直接或通过连接片段与其它生物活性物质偶联。
- 一种组合物,其特征在于:其含有权利要求1-12任一项的抗OX40抗体或其抗原结合部分、权利要求13-20的核酸分子、权利要求21的载体、权利要求22的宿主细胞、或者权利要求23的偶联物,以及任选的药学上可接受的 载体或赋形剂,以及任选的其它生物活性物质。
- 权利要求1-12任一项的抗OX40抗体或其抗原结合部分、权利要求13-20的核酸分子、权利要求21的载体、权利要求22的宿主细胞、权利要求23的偶联物、或者权利要求24的组合物用于制备预防或***的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110853915.7A CN114380908B (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/091958 WO2017063162A1 (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110853915.7A Division CN114380908B (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108137684A true CN108137684A (zh) | 2018-06-08 |
CN108137684B CN108137684B (zh) | 2022-03-08 |
Family
ID=58516967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580083716.5A Active CN108137684B (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
CN202110853915.7A Active CN114380908B (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110853915.7A Active CN114380908B (zh) | 2015-10-15 | 2015-10-15 | 抗ox40抗体及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10624974B2 (zh) |
EP (1) | EP3363816A4 (zh) |
JP (1) | JP6771551B2 (zh) |
CN (2) | CN108137684B (zh) |
WO (1) | WO2017063162A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110172090A (zh) * | 2019-06-03 | 2019-08-27 | 北京岳昊科技发展有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
CN112279915A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Icos抗体、基因、载体、宿主细胞和icos拮抗剂 |
CN112279914A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂 |
CN112279916A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Il13ra1抗体、基因、载体、宿主细胞和il13ra1拮抗剂 |
CN112300277A (zh) * | 2019-07-25 | 2021-02-02 | 苏州丁孚靶点生物技术有限公司 | Csf1r抗体、基因、载体、宿主细胞和csf1r拮抗剂 |
CN112867737A (zh) * | 2018-10-19 | 2021-05-28 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
SG11202003443TA (en) * | 2017-11-24 | 2020-05-28 | Eucure Beijing Biopharma Co Ltd | Anti-ox40 antibodies and uses thereof |
CN110092832B (zh) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
JP7411575B2 (ja) | 2018-05-11 | 2024-01-11 | ウーシー・バイオロジクス・(シャンハイ)・カンパニー・リミテッド | Ox40に対する完全ヒト抗体、それを調製する方法、およびその使用 |
SG11202011024WA (en) * | 2018-05-23 | 2020-12-30 | Beigene Ltd | Anti-ox40 antibodies and methods of use |
US20220017629A1 (en) * | 2018-11-20 | 2022-01-20 | Shanghai Pharmaexplorer Co., Ltd. | Ox40 antibody, preparation method thereof and use thereof |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
MX2023007734A (es) | 2020-12-28 | 2023-08-21 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de las mismas. |
JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101684157A (zh) * | 2004-09-17 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
CN102741287A (zh) * | 2009-02-17 | 2012-10-17 | Ucb制药公司 | 对人ox40具有特异性的抗体分子 |
CN103221427A (zh) * | 2010-08-23 | 2013-07-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
CN103717263A (zh) * | 2011-07-11 | 2014-04-09 | 格兰马克药品股份有限公司 | 结合ox40的抗体及其用途 |
CN103946240A (zh) * | 2011-11-11 | 2014-07-23 | Ucb医药有限公司 | 对人ox40具有特异性的抗体分子 |
CN103946238A (zh) * | 2011-08-23 | 2014-07-23 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
WO2014148895A1 (en) * | 2013-03-18 | 2014-09-25 | Biocerox Products B.V. | Humanized anti-cd134 (ox40) antibodies and uses thereof |
CN104080809A (zh) * | 2011-09-16 | 2014-10-01 | 比奥塞罗克斯产品公司 | 抗cd134(ox40)抗体及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2295639T3 (es) * | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
CN101023102B (zh) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
US20100136030A1 (en) * | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
PT2851374T (pt) * | 2007-12-14 | 2017-06-20 | Pfizer | Moléculas de ligação ao recetor humano ox40 |
MX2016012779A (es) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
HUE046767T2 (hu) | 2014-03-31 | 2020-03-30 | Hoffmann La Roche | Anti-OX40 antitestek és alkalmazási eljárások |
TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
-
2015
- 2015-10-15 JP JP2018519051A patent/JP6771551B2/ja active Active
- 2015-10-15 WO PCT/CN2015/091958 patent/WO2017063162A1/zh active Application Filing
- 2015-10-15 EP EP15906047.4A patent/EP3363816A4/en active Pending
- 2015-10-15 US US15/768,242 patent/US10624974B2/en active Active
- 2015-10-15 CN CN201580083716.5A patent/CN108137684B/zh active Active
- 2015-10-15 CN CN202110853915.7A patent/CN114380908B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101684157A (zh) * | 2004-09-17 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
CN102741287A (zh) * | 2009-02-17 | 2012-10-17 | Ucb制药公司 | 对人ox40具有特异性的抗体分子 |
CN103221427A (zh) * | 2010-08-23 | 2013-07-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
CN103717263A (zh) * | 2011-07-11 | 2014-04-09 | 格兰马克药品股份有限公司 | 结合ox40的抗体及其用途 |
CN103946238A (zh) * | 2011-08-23 | 2014-07-23 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
CN104080809A (zh) * | 2011-09-16 | 2014-10-01 | 比奥塞罗克斯产品公司 | 抗cd134(ox40)抗体及其应用 |
CN103946240A (zh) * | 2011-11-11 | 2014-07-23 | Ucb医药有限公司 | 对人ox40具有特异性的抗体分子 |
WO2014148895A1 (en) * | 2013-03-18 | 2014-09-25 | Biocerox Products B.V. | Humanized anti-cd134 (ox40) antibodies and uses thereof |
Non-Patent Citations (1)
Title |
---|
LI等: "Effect of antibody to CD134 on perforin-mediated cytolysis in human peripheral blood mononuclear cells", 《HYBRIDOMA》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112867737A (zh) * | 2018-10-19 | 2021-05-28 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
CN112867737B (zh) * | 2018-10-19 | 2023-01-06 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
CN110172090A (zh) * | 2019-06-03 | 2019-08-27 | 北京岳昊科技发展有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
CN112279915A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Icos抗体、基因、载体、宿主细胞和icos拮抗剂 |
CN112279914A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂 |
CN112279916A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Il13ra1抗体、基因、载体、宿主细胞和il13ra1拮抗剂 |
CN112300277A (zh) * | 2019-07-25 | 2021-02-02 | 苏州丁孚靶点生物技术有限公司 | Csf1r抗体、基因、载体、宿主细胞和csf1r拮抗剂 |
Also Published As
Publication number | Publication date |
---|---|
US20180339059A1 (en) | 2018-11-29 |
JP2018534924A (ja) | 2018-11-29 |
CN114380908B (zh) | 2023-03-17 |
WO2017063162A1 (zh) | 2017-04-20 |
CN108137684B (zh) | 2022-03-08 |
US10624974B2 (en) | 2020-04-21 |
EP3363816A1 (en) | 2018-08-22 |
CN114380908A (zh) | 2022-04-22 |
JP6771551B2 (ja) | 2020-10-21 |
EP3363816A4 (en) | 2019-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108137684A (zh) | 抗ox40抗体及其应用 | |
CN105777906B (zh) | 抗pd-l1全人抗体及其应用 | |
TWI823895B (zh) | 抗b7-h4抗體、其抗原結合片段及其醫藥用途 | |
WO2021063330A1 (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
CN108026169A (zh) | 抗人cd137的完全人抗体及其应用 | |
US20210115143A1 (en) | Anti-pd-l1 antibody and use thereof | |
KR20220104783A (ko) | Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질 | |
EP3988573A1 (en) | Anti-cd3e/bcma bispecific antibody and use thereof | |
TWI713464B (zh) | 針對Fcγ受體IIB及Fcε受體的新穎抗體 | |
US20230071422A1 (en) | ANTI-CD3 and ANTI-CD123 Bispecific Antibody and Use Thereof | |
JP2022532173A (ja) | ヒト化抗cd137抗体およびその使用 | |
JP2021505206A (ja) | 抗cd137抗体およびその使用 | |
TW202112826A (zh) | 抗tigit抗體及使用方法 | |
EP3856790A2 (en) | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof | |
AU2019349874A1 (en) | Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof | |
WO2022188721A1 (zh) | 抗pvrig蛋白抗体或抗体片段及其用途 | |
WO2020058762A1 (en) | Antibodies specific to ctla-4 and uses thereof | |
KR20210005082A (ko) | 항-cd40 항체 및 이의 용도 | |
TWI839395B (zh) | 靶向cd137的抗體及其使用方法 | |
WO2023236844A1 (zh) | 靶向her2和pd-l1的双特异性抗体及其制备方法和应用 | |
TWI802923B (zh) | 標靶ox40的抗體及其製備方法和應用 | |
WO2024067759A1 (zh) | 一种能够结合cldn18.2的抗体或其抗原结合片段及其应用 | |
WO2023138639A1 (zh) | 靶向tigit的抗原结合蛋白及其用途 | |
CN116133684A (zh) | 抗人nr1抗体衍生物 | |
CN116003625A (zh) | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Ting Inventor after: Fei Yeqiong Inventor after: Zhao Meng Inventor after: Luan Yan Inventor after: Wang Popo Inventor after: Peng Jianjian Inventor after: Ma Shuli Inventor after: Ma Hui Inventor after: Pan Xiaolong Inventor after: Fu Shilong Inventor after: Ning Panpan Inventor before: Xu Ting Inventor before: Fei Yeqiong Inventor before: Zhao Meng Inventor before: Luan Yan Inventor before: Wang Popo Inventor before: Peng Jianjian Inventor before: Ma Shuli Inventor before: Ma Hui Inventor before: Pan Xiaolong Inventor before: Fu Shilong Inventor before: Ning Shanshan |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |